{"address1": "60 Jubilee Avenue", "address2": "Milton Park", "city": "Abingdon", "zip": "OX14 4RX", "country": "United Kingdom", "phone": "44 12 3543 0000", "fax": "44 12 3543 0001", "website": "https://www.adaptimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.", "fullTimeEmployees": 506, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adrian G.  Rawcliffe", "age": 52, "title": "CEO, Principal Accounting Officer & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1057878, "exercisedValue": 199161, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen Katrina Tayton-Martin MBA, Ph.D.", "age": 57, "title": "Co-Founder & Chief Business & Strategy Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 677404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gavin Hilary James Wood ACA, BA (Hons)", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 666344, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William C. A. Bertrand Jr., Esq., J.D.", "age": 59, "title": "COO & Chief Compliance Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 707338, "exercisedValue": 76949, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elliot  Norry B.A., M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 676194, "exercisedValue": 65024, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joanna  Brewer Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juli P. Miller Ph.D.", "title": "VP of Corporate Affairs & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kerry  Sharp", "title": "Senior VP & General Council", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dana  Lynch", "title": "Senior Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Lunger", "age": 54, "title": "Chief Patient Supply Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 645908, "exercisedValue": 148202, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.197, "open": 0.1951, "dayLow": 0.1951, "dayHigh": 0.2512, "regularMarketPreviousClose": 0.197, "regularMarketOpen": 0.1951, "regularMarketDayLow": 0.1951, "regularMarketDayHigh": 0.2512, "payoutRatio": 0.0, "beta": 2.511, "forwardPE": -0.65789473, "volume": 5891115, "regularMarketVolume": 5891115, "averageVolume": 1607248, "averageVolume10days": 4242010, "averageDailyVolume10Day": 4242010, "bid": 0.1726, "ask": 0.2731, "bidSize": 1, "askSize": 1, "marketCap": 64308000, "fiftyTwoWeekLow": 0.195, "fiftyTwoWeekHigh": 1.48, "priceToSalesTrailing12Months": 0.36121595, "fiftyDayAverage": 0.49088, "twoHundredDayAverage": 0.80376, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 308451904, "profitMargins": -0.39776, "floatShares": 1052778310, "sharesOutstanding": 257232000, "sharesShort": 5642793, "sharesShortPriorMonth": 7190442, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.022, "heldPercentInsiders": 0.0030899998, "heldPercentInstitutions": 0.4959, "shortRatio": 4.59, "shortPercentOfFloat": 0.033099998, "impliedSharesOutstanding": 226172000, "bookValue": 0.046, "priceToBook": 5.4347825, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -70814000, "trailingEps": -0.3, "forwardEps": -0.38, "enterpriseToRevenue": 1.733, "enterpriseToEbitda": -7.49, "52WeekChange": -0.81884056, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.25, "targetHighPrice": 3.0, "targetLowPrice": 1.0, "targetMeanPrice": 1.70625, "targetMedianPrice": 1.5, "recommendationMean": 2.28571, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 151604992, "totalCashPerShare": 0.098, "ebitda": -41184000, "totalDebt": 74209000, "quickRatio": 2.597, "currentRatio": 2.916, "totalRevenue": 178032000, "debtToEquity": 626.289, "revenuePerShare": 0.706, "returnOnAssets": -0.12394, "returnOnEquity": -2.7574499, "grossProfits": 28902000, "freeCashflow": 2171875, "operatingCashflow": -73206000, "revenueGrowth": 12.948, "grossMargins": 0.16233999, "ebitdaMargins": -0.23132999, "operatingMargins": -20.02297, "financialCurrency": "USD", "symbol": "ADAP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "preMarketTime": 1743593036, "regularMarketTime": 1743537601, "marketState": "PRE", "regularMarketChangePercent": 26.903555, "regularMarketPrice": 0.25, "shortName": "Adaptimmune Therapeutics plc", "longName": "Adaptimmune Therapeutics plc", "exchange": "NMS", "messageBoardId": "finmb_113495056", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "preMarketChange": 0.0038000047, "preMarketChangePercent": 1.5200019, "preMarketPrice": 0.2538, "regularMarketChange": 0.053000003, "regularMarketDayRange": "0.1951 - 0.2512", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1607248, "fiftyTwoWeekLowChange": 0.055000007, "fiftyTwoWeekLowChangePercent": 0.28205132, "fiftyTwoWeekRange": "0.195 - 1.48", "fiftyTwoWeekHighChange": -1.23, "fiftyTwoWeekHighChangePercent": -0.8310811, "fiftyTwoWeekChangePercent": -81.884056, "dividendDate": 1522368000, "earningsTimestamp": 1742468421, "earningsTimestampStart": 1747166400, "earningsTimestampEnd": 1747512000, "earningsCallTimestampStart": 1742472000, "earningsCallTimestampEnd": 1742472000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.3, "epsForward": -0.38, "epsCurrentYear": -0.489, "priceEpsCurrentYear": -0.51124746, "fiftyDayAverageChange": -0.24088001, "fiftyDayAverageChangePercent": -0.4907106, "twoHundredDayAverageChange": -0.55376, "twoHundredDayAverageChangePercent": -0.68896186, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430919000000, "displayName": "Adaptimmune Therapeutics", "trailingPegRatio": null}